DAIC
JUNE 4, 2024
The Neuroguard Integrated Embolic Protection (IEP) system is an experimental treatment for carotid artery stenosis, also known as carotid artery disease, a condition in which fatty-waxy deposits known as plaque builds up and blocks the normal flow of blood in the large arteries on either side of the neck.
DAIC
APRIL 12, 2024
We are committed to advancing the field of interventional cardiology and improving patient outcomes through innovation." This designation expedites the development, assessment, and review process, enabling patients to gain access to innovative medical technologies more quickly.
DAIC
JUNE 18, 2024
The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. of the U.S. population.
DAIC
JANUARY 17, 2024
At present, machine learning, deep learning, and other AI technologies have been tried to be applied to intelligent diagnostic and decision making, image interpretation, accurate classification, and prognostication of cardiovascular diseases, which has led to broad application prospects and innovation potential.
Frontiers in Cardiovascular Medicine
JUNE 16, 2024
In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques.
DAIC
NOVEMBER 8, 2024
THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter that integrates two critical PAD treatments into a single device. The innovative feature of the Philips catheter is that both the atherectomy and lithotripsy are laser-driven. clinical trial,” said Dr.
DAIC
DECEMBER 5, 2024
This funding will allow us to expand our commercial reach, which is especially germane following our recent achievements in attaining Medicare coverage and a CPT Category I code for advanced plaque analysis. Until Cleerly, healthcare providers have had no way to easily and completely assess plaque burden in a non-invasive manner.
Expert insights. Personalized for you.
111 
Let's personalize your content